Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Journal of Oncology Nursing

• Publication date

  2008-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1188/08.CJON.445-454PMID 18515243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2008

  2008cited by this paper
• Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.

  2007cited by this paper
• Symptom Clusters and Quality of Life in Survivors of Ovarian Cancer

  2007cited by this paper
• Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.

  2006cited by this paper
• Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis.

  2006cited by this paper
• Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: a pilot study.

  2006cited by this paper
• Mood States Associated with Transitory Physical Symptoms Among Breast and Ovarian Cancer Survivors

  2006cited by this paper
• Primary surgery for ovarian cancer.

  2006cited by this paper
• Ovarian cancer patients' psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem.

  2005cited by this paper
• Representations of fatigue in women receiving chemotherapy for gynecologic cancers.

  2005cited by this paper
• A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.

  2005cited by this paper
• Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

  2004cited by this paper
• Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

  2004cited by this paper
• Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study

  2003cited by this paper
• Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.

  2003cited by this paper
• Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.

  2003cited by this paper
• Quality of Life Immediately After Peripheral Blood Stem Cell Transplantation

  2003cited by this paper
• Fatigue in ovarian carcinoma patients

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

  2003influential reference
• Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

  2002cited by this paper
• Fatigue in patients with cancer.

  2002cited by this paper
• The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy.

  2002cited by this paper
• The impact of hemoglobin levels on fatigue and quality of life in cancer patients.

  2002cited by this paper
• Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

  2001cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• Physical Functioning of Elderly Cancer Patients Prior to Diagnosis and Following Initial Treatment

  2001cited by this paper
• Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment.

  2001cited by this paper
• Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.

  2000cited by this paper
• NCCN Practice Guidelines for Cancer-Related Fatigue.

  2000cited by this paper
• The Impact of Fatigue on Patients with Cancer: Overview of FATIGUE 1 and 2.

  2000cited by this paper
• Sleep and fatigue.

  2000cited by this paper
• Cancer-related fatigue. Suffering a different fatigue.

  2000cited by this paper
• Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.

  2000cited by this paper
• Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study.

  2000cited by this paper
• Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

  2000cited by this paper
• Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

  1999cited by this paper
• Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

  1999cited by this paper
• Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates.

  1999influential reference
• Cancer-related fatigue: guidelines for evaluation and management.

  1999cited by this paper
• Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy.

  1998cited by this paper
• Fatigue in patients with cancer. Analysis and assessment.

  1998cited by this paper
• Quality of Life in Women with Ovarian Cancer

  1997cited by this paper
• Pattern of association over time of side-effects burden, self-help, and self-care in women with breast cancer.

  1997cited by this paper
• Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.

  1997cited by this paper
• Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

  1995cited by this paper
• Quality of life of women with ovarian cancer.

  1995cited by this paper
• Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms

  1994cited by this paper
• Fatigue and the cancer experience: the state of the knowledge.

  1994cited by this paper
• Fatigue in cancer patients.

  1993cited by this paper
• Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

  1992cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Fatigue in cancer patients: A descriptive study

  1991cited by this paper
• Correlates of fatigue in people with breast or lung cancer.

  1991cited by this paper
• A critical appraisal of the research literature investigating fatigue in the individual with cancer

  1991cited by this paper
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

  1989cited by this paper
• Fatigue in the cancer patient: a conceptual approach to a clinical problem.

  1987cited by this paper
• A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

  1986cited by this paper
• Totally implantable system for peritoneal access.

  1984cited by this paper
• Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.

  1979cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper

• Advanced Ovarian Cancer Patients' Experiences of Surgical Treatment: A Qualitative Analysis.

  2024cites this paper
• Cancer-Related Fatigue in Breast and Gynecologic Cancers

  2021cites this paper
• Prevalence of and factors related to anxiety and depression symptoms among married patients with gynecological malignancies in China.

  2018cites this paper
• Effects of nurse-led home-based exercise & cognitive behavioral therapy on reducing cancer-related fatigue in patients with ovarian cancer during and after chemotherapy: A randomized controlled trial.

  2017cites this paper
• Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers

  2015cites this paper
• Cancer-related and treatment-related fatigue.

  2015cites this paper
• Cancer-Related Concerns Among Women With a New Diagnosis of Gynecological Cancer: An Exploration of Age Group Differences

  2014cites this paper
• Peritoneal carcinomatosis from advanced ovarian cancer: To treat or not to treat ethical issues suggested by a case study

  2014cites this paper
• Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

  2013cites this paper
• Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer.

  2013cites this paper
• Social-cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers.

  2013cites this paper
• Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study.

  2013cites this paper
• Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy

  2012cites this paper
• Characterizing Fatigue: The Effects of Ethnicity and Acculturation.

  2012cites this paper
• Non‐pharmacological interventions for cancer‐related fatigue in men treated for prostate cancer: A systematic review.

  2012cites this paper
• Intraperitoneal chemotherapy for ovarian cancer.

  2012cites this paper
• Named Series: Fatigue, Brain, Behavior, and Immunity Sleep disturbance, cytokines, and fatigue in women with ovarian cancer q

  2012cites this paper
• Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

  2012cites this paper
• Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy

  2011cites this paper
• Non-pharmacological interventions for cancer-related fatigue in men with prostate cancer undergoing treatment: A systematic review.

  2011cites this paper